This trial has not yet started – enrolment for this trial has not yet commenced. Depending on eligibility, you may be able to enrol in this trial at a later date.
About this trial
The purpose of this study is to see if giving antiretroviralsA medication or other substance which is active against retroviruses such as HIV. to people soon after they have been infected with HIV can help them control HIV. The study will also see if the immune system can control the amount of HIV virusA small infective organism which is incapable of reproducing outside a host cell. in the blood (viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma.) even after a person has stopped taking the medications. The study will evaluate three different schedules of stopping and starting anti-HIV medications to see which schedule is best able to boost a patient's immune system to control HIV viral load.
Background information
People recently infected with HIV who are treated with anti-HIV medications may develop strong immune system responses to HIV and may be able to control the virusA small infective organism which is incapable of reproducing outside a host cell. without continuing to take these medications.
| Official title: | A Randomized, Multicenter Trial to Determine Whether Induction Therapy Followed by Treatment Interruption is Superior to Induction Therapy Alone in the Treatment of Primary HIV Infection (PHI): The Structured Treatment Interruption (STI) Study |
|---|
| What is this trial studying? | Treatment strategy |
|---|
| Start date: | September 2009 This may be the proposed or expected start date for trials which have not yet started. |
|---|
| How many participants will this trial enrol? | 120 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
|---|
| How long is this trial planned to go for? | Participants in this trial will be asked to follow the treatment strategy for 2 years. |
|---|
| Links to further information: | |
|---|
Who can enrol in this trial?
You may be eligible to participate in this trial if you meet the following criteria:
- At least 18 years old
- Have never taken HIV treatments
- Recently been infected with HIV, or undergoing seroconversion
This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.
This site complies with the HONcode standard for trustworthy health information: verify here. 
